LAX.SH
AUROBINDO PHARMA LTD·PHARMACEUTICALS 70.24·Pharmaceuticals & Biotechnology Companies
Price
1,621.3
+0.82%52W Range
Market Cap
₹93,286.02 Cr
Traded: ₹120.74 Cr (0.13%) 0.0x
Free Float: ₹6,110.23 Cr (1.98% of FF traded)
Volume · 60D trend
7.5 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | +15.0% | +12.0% | +10.0% | -- | -- | Decelerating |
| Sales | +10.0% | +7.0% | +11.0% | -- | +7.0% | Stable |
| Profit | +8.0% | +4.0% | +8.0% | -- | -1.0% | Stable |
| Return | +5.0% | +8.0% | +39.0% | +12.0% | -- | Stable |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 9,150 | 8,853 | 8,646 | 8,286 | 7,868 | 8,382 | 7,979 | 7,796 | 7,567 | 7,580 | 7,352 | 7,219 | 6,851 | 6,473 | 6,407 | 5,739 |
| Expenses | 7,271 | 7,103 | 6,873 | 6,608 | 6,265 | 6,622 | 6,401 | 6,230 | 5,949 | 5,920 | 5,753 | 5,846 | 5,702 | 5,477 | 5,453 | 4,950 |
| Operating Profit | 1,880 | 1,750 | 1,773 | 1,678 | 1,603 | 1,760 | 1,578 | 1,566 | 1,618 | 1,660 | 1,599 | 1,373 | 1,149 | 996 | 954 | 790 |
| OPM % | 21.0% | 20.0% | 21.0% | 20.0% | 20.0% | 21.0% | 20.0% | 20.0% | 21.0% | 22.0% | 22.0% | 19.0% | 17.0% | 15.0% | 15.0% | 14.0% |
| Other Income | 224 | 117 | 123 | 122 | 107 | 135 | 159 | 136 | 221 | 14 | 163 | 188 | 47 | 135 | 93 | 57 |
| Interest | 102 | 98 | 93 | 95 | 98 | 115 | 118 | 113 | 111 | 89 | 76 | 68 | 57 | 56 | 45 | 25 |
| Depreciation | 487 | 479 | 465 | 429 | 406 | 444 | 419 | 382 | 404 | 354 | 423 | 418 | 327 | 346 | 321 | 298 |
| Profit Before Tax | 1,515 | 1,291 | 1,339 | 1,276 | 1,207 | 1,335 | 1,200 | 1,207 | 1,324 | 1,230 | 1,262 | 1,076 | 812 | 730 | 680 | 523 |
| Tax % | 32.0% | 29.0% | 32.0% | 34.0% | 32.0% | 32.0% | 30.0% | 32.0% | 31.0% | 26.0% | 26.0% | 30.0% | 30.0% | 31.0% | 28.0% | 22.0% |
| Net Profit | 1,032 | 921 | 910 | 848 | 824 | 903 | 846 | 817 | 918 | 907 | 940 | 752 | 570 | 506 | 491 | 410 |
| Exceptional Items | -- | 0 | -65 | 0 | 0 | 0 | 0 | 0 | 0 | -122 | 0 | 0 | -70 | 0 | 0 | 0 |
| EPS (Rs) | 17.8 | 15.9 | 15.7 | 14.6 | 14.2 | 15.6 | 14.6 | 14.1 | 15.7 | 15.5 | 16.0 | 12.9 | 9.7 | 8.6 | 8.4 | 7.0 |
| Sales Growth (YoY) | -- | 5.6% | 8.4% | 6.3% | 4.0% | 10.6% | 8.5% | 8.0% | 10.5% | 17.1% | 14.7% | 25.8% | 9.9% | 11.4% | -- | -- |
| Sales Growth (QoQ) | -- | 2.4% | 4.3% | 5.3% | -6.1% | 5.0% | 2.4% | 3.0% | -0.2% | 3.1% | 1.8% | 5.4% | 5.8% | 1.0% | 11.6% | -- |
| OP Growth (YoY) | 17.3% | -0.6% | 12.4% | 7.2% | -0.9% | 6.0% | -1.3% | 14.1% | 40.8% | 66.7% | 67.6% | 73.8% | -- | -- | -- | -- |
| OP Growth (QoQ) | 7.4% | -1.3% | 5.7% | 4.7% | -8.9% | 11.5% | 0.8% | -3.2% | -2.5% | 3.8% | 16.5% | 19.5% | 15.4% | 4.4% | 20.8% | -- |
| Profit Growth (YoY) | -- | 2.0% | 13.0% | 4.0% | -10.0% | -7.0% | -10.0% | 8.0% | 50.0% | 92.0% | 91.0% | 85.0% | 17.0% | -31.0% | -15.0% | -41.0% |
| EPS Growth (YoY) | -- | 1.9% | 7.6% | 3.8% | -9.5% | 0.3% | -8.9% | 8.9% | 61.1% | 79.5% | 90.7% | 84.8% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 1.2% | 7.3% | 2.9% | -8.7% | 6.9% | 3.5% | -10.3% | 1.2% | -2.9% | 23.7% | 32.6% | 12.7% | 3.1% | 19.9% | -- |
| OP Margin | -- | 19.8% | 20.5% | 20.3% | 20.4% | 21.0% | 19.8% | 20.1% | 21.4% | 21.9% | 21.8% | 19.0% | 16.8% | 15.4% | 14.9% | 13.8% |
| Net Margin | -- | 10.4% | 10.5% | 10.2% | 10.5% | 10.8% | 10.6% | 10.5% | 12.1% | 12.0% | 12.8% | 10.4% | 8.3% | 7.8% | 7.7% | 7.1% |
| Material Cost % | -- | 38.7% | 40.3% | 40.3% | 41.2% | 40.9% | 41.5% | 41.2% | 40.6% | 40.4% | 42.9% | 44.8% | 46.0% | 45.3% | 45.4% | 44.7% |
| Employee Cost % | -- | 15.5% | 15.2% | 15.4% | 15.6% | 13.9% | 14.2% | 14.2% | 14.2% | 13.5% | 13.5% | 13.2% | 13.9% | 13.2% | 14.4% | 15.1% |
| P/S | 2.67 | 2.76 | 2.71 | 2.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 25.36 | 26.74 | 25.76 | 20.71 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 2.46 | 2.45 | 2.56 | 2.02 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Intimation of completion of US FDA inspection at Lannett Company LLC., a wholly owned subsidiary of Aurobindo Pharma, USA Inc.
Intimation of completion of US FDA inspection at Auro Peptides Limited, a subsidiary of the Company.
Intimation of classification of US FDA inspection at Raleigh Plant, North Carolina, owned by Aurolife LLF, a wholly owned step down subsidiary of the Company, as Voluntary Actioin Indicated (VAI).
Intimation of receipt of warning letter from US FDA by Unit 1 of Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company.
Intimation of participation of officials of the Company in investors / analysts meet to be held on August 19, 2026
Intimation of incorporation of a new wholly owned subsidiary.
Submission of transcript of the earning call on the unaudited financial results for the quarter ended June 30, 2026.
Submission of copies of notice published by the Company on August 7, 2026 in Business Standard and Nava Telangana regarding special window for re-lodgement of transfer requests of physical shares.
Submission of copies of newspaper advertisements of the financial results of the Company for the first quarter ended June 30, 2026 as published in Business Standard and Nava Telangana on ....
Intimation of participation by the officials of the Company in the Investor/Analyst Meet to be held on August 11 to 13, 2026 in Singapore & Hong Kong
The Board of Directors of the Company at its meeting held today, August 5, 2026, has, inter alia, considered and approved: a) the standalone and consolidated Unaudited Financial Results ....
Submission of Notice of 39th Annual General Meeting of the Company to be held August 27, 2026.
Submission of BRSR for FY 2025-26.
Submission of Integrated Annual Report 2025-26
Intimation of 39th Annual General Meeting of Aurobindo Pharma Limited to be held on August 27, 2026.
Aurobindo Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve Intimation of Board Meeting ....
Submission of press release that is being issued in connection with signing non exclusive voluntary license agreement with MSD.
Intimation of acquisition of majority ownership control in A1 Biochem Labs (India) Private Limited and A1 Biochem Labs LLC, USA.
Intimation of acquisition of a new stepdown subsidiary.
Intimation of completion of transfer of Company''s domestic branded generic pharmaceutical formulations products business to Auropharm Limited, a wholly owned subsidiary of the Company.
Submission of certificate under regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended June 30, 2026.
Intimation of completion of acquisition of Lannet by Aurobindo Pharma USA Inc, a wholly owned subsidiary of the Company.
Intimation of completion of US FDA inspection at Auroactive Pharma Private Limited, a wholly owned subsidiary of the Company.
Intimation of closure of Trading Window
Intimation of completion of acquisition.
Submission of Press Release that is being issued by the Company.
Intimation of receipt of necessary approvals from US Federal Trade Commission (FTC) for the acquisition of Lannett business.
Intimation of completion of US FDA Pre-Approval Inspection (PAI) at Eugia Steriles Private Limited, a 100% stepdown subsidiary of the Company.
Intimation of US FDA Inspection at Unit-III of Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company as OAI.
Submission of notice published in the newspapers.
Intimation of Participation in Investor meeting to be held on June 12, 2026
Intimation of Participation in Investor meet at BofA 2026 India Conference at Mumbai
Intimation of Investor meet at Investec US Pharma and Healthcare Bus Tour 7.0 in New Jersey, USA.
Submission of earning calls transcript.
Intimation of investor meet to be held on Mary 29, 2026.
Intimation of classification of Unit-1 of Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company.
Submission of copies of financial results published in newspapers.
Intimation of incorporation of a new stepdown subsidiary in France.
Intimation of outcome of Board meeting held on May 21, 2026.
Submission of Press Release on Audited Financial Results for the year ended March 31, 2026.
Intimation of re-appointment of Internal Auditor.
Intimation of resignation of MRR & Associates, Company Secretaries as secretarial auditor of the Company.
Intimation of appointment of RPR & Associates as Secretarial Auditor of the Company.
Submission of Investor Presentation on Q4 FY26 Financial Results.
Submission of the Financial Results for the year ended March 31, 2026
Curateq Biologics Private Limited, a wholly owned subsidiary of the Company receives CDSCO Marketing Autorisation (Form CT 23) for Bevqolva (Bevacizumab Biosimilar).
intimation of receipt of Order form the Hon''ble High Court of Telangana, Hyderabad by the promoters of the Company.
Submission of certificate of extinguishment of 5423728 equity shares of Re.1/- of the Company bought back from the shareholders of the Company under Buyback Offer.
Intimation of schedule of Earnings Call to be held on May 22, 2026 at 8:30 AM (IST) on Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2026.
Aurobindo Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve the Standalone & Consolidated ....
Annual Reports
14Credit Ratings
6Concalls
75Feb 2026
28 Feb 2026Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025Jun 2025
30 Jun 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023Jun 2023
30 Jun 2023Feb 2023
28 Feb 2023Feb 2023
28 Feb 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022Jun 2022
30 Jun 2022Feb 2022
28 Feb 2022Nov 2021
30 Nov 2021Sep 2021
30 Sept 2021Aug 2021
31 Aug 2021Jun 2021
30 Jun 2021Feb 2021
28 Feb 2021Nov 2020
30 Nov 2020Aug 2020
31 Aug 2020Jun 2020
30 Jun 2020Feb 2020
29 Feb 2020Feb 2020
29 Feb 2020Jan 2020
31 Jan 2020Nov 2019
30 Nov 2019Nov 2019
30 Nov 2019Aug 2019
31 Aug 2019Aug 2019
31 Aug 2019Aug 2019
31 Aug 2019Jun 2019
30 Jun 2019May 2019
31 May 2019Mar 2019
31 Mar 2019Feb 2019
28 Feb 2019Feb 2019
28 Feb 2019Jan 2019
31 Jan 2019Nov 2018
30 Nov 2018Nov 2018
30 Nov 2018Sep 2018
30 Sept 2018Sep 2018
30 Sept 2018Aug 2018
31 Aug 2018Aug 2018
31 Aug 2018Jun 2018
30 Jun 2018May 2018
31 May 2018Mar 2018
31 Mar 2018Feb 2018
28 Feb 2018Feb 2018
28 Feb 2018Feb 2018
28 Feb 2018Jan 2018
31 Jan 2018Nov 2017
30 Nov 2017Nov 2017
30 Nov 2017Sep 2017
30 Sept 2017Aug 2017
31 Aug 2017Aug 2017
31 Aug 2017Jun 2017
30 Jun 2017Jun 2017
30 Jun 2017Jun 2017
30 Jun 2017May 2017
31 May 2017Mar 2017
31 Mar 2017Feb 2017
28 Feb 2017Feb 2017
28 Feb 2017Nov 2016
30 Nov 2016Nov 2016
30 Nov 2016Sep 2016
30 Sept 2016Sep 2016
30 Sept 2016Aug 2016
31 Aug 2016Aug 2016
31 Aug 2016Jun 2016
30 Jun 2016Feb 2016
29 Feb 2016Held by ETFs
38 ETFs hold auropharma · sorted by weight
Held by Mutual Funds
134 schemes hold auropharma · sorted by weight